ProCE Banner Activity

RELATIVITY-047: 2-Yr Update of First-line Nivolumab + Relatlimab vs Nivolumab in Advanced Melanoma

Conference Coverage

In this 2-year update of the RELATIVITY-047 trial, nivolumab plus relatlimab maintained a PFS and ORR benefit vs nivolumab alone in patients with advanced melanoma.

Released: June 08, 2023


Provided by

Provided by Clincal Care Options, LLC

ProCE Banner


Supported by educational grants from Merck Sharp & Dohme Corp. and Regeneron Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Regeneron Pharmaceuticals, Inc